Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells

Leukemia Research
H J DeegF Appelbaum

Abstract

Myelodysplastic syndrome (MDS) comprises a spectrum of heterogeneous diseases. Most patients present with ineffective hematopoiesis. The pathophysiology involves immune-mediated effects, cytokine dysregulation, and apoptosis, among others. We treated 14 transfusion-requiring patients with MDS, 10 with refractory anemia (RA) and four with RA with excess blasts (RAEB) with a 4-day course of antithymocyte globulin (ATG) followed by intermittent etanercept for 4 months. Among 13 evaluable patients, five are red blood cell and platelet transfusion independent for intervals extending beyond 2 years, and two have normalized their peripheral blood parameters. One additional patient showed a transient rise of platelet and neutrophil counts, for an overall response rate of 46%. Responding patients showed striking improvements in marrow cell abnormalities as characterized by flow cytometry. These data show that a combination of ATG plus etanercept offers effective palliative therapy for unselected patients with MDS. Further trials incorporating these two agents are warranted.

Citations

Jan 1, 2008·Current Hematologic Malignancy Reports·A John Barrett, Elaine M Sloand
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·A Mario MarcondesH Joachim Deeg
Jan 12, 2010·Annual Review of Medicine·Bart L Scott, H Joachim Deeg
Feb 15, 2008·PLoS Medicine·Jerald Radich
Nov 21, 2012·Expert Opinion on Emerging Drugs·Pearlie K Epling-BurnetteAlan F List
Aug 9, 2005·Expert Opinion on Emerging Drugs·Philip J Nivatpumin, Steven D Gore
Jul 14, 2010·Seminars in Hematology·Jeffrey BryanHagop Kantarjian
Mar 31, 2009·Seminars in Hematology·Adam M Boruchov
Mar 31, 2009·Hematology/oncology Clinics of North America·Elaine M Sloand
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
Jan 9, 2008·Seminars in Hematology·Elaine M Sloand, Katayoun Rezvani
Sep 11, 2007·Leukemia Research·Denise A Wells, Kiyoyuki Ogata
Aug 24, 2007·Leukemia Research·Arjan A van de LoosdrechtGert J Ossenkoppele
Mar 25, 2010·British Journal of Haematology·Bart L ScottH Joachim Deeg
Sep 24, 2004·Leukemia Research·A John Barrett
Mar 10, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Li YanMarian T Nakada
Oct 28, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·H Joachim Deeg
Feb 11, 2015·Cellular and Molecular Life Sciences : CMLS·Lili YangSheng Wei
Nov 1, 2006·Bone Marrow Transplantation·J M HowsUNKNOWN Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Sep 30, 2017·The Cochrane Database of Systematic Reviews·Helga DodilletNicole Skoetz
Jul 20, 2018·Expert Review of Hematology·Rory M ShallisAmer M Zeidan
Mar 17, 2007·Cancer·Hagop KantarjianJoseph Leveque
Apr 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elena SpinelliValeria Santini
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna BoulaHelen A Papadaki
Jan 7, 2021·Cancers·Bruno FattizzoChiara Caprioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis